A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration.

ABSTRACT:

Purpose

What are the patient characteristics predictive of response to ranibizumab treatment?

Methods

Model-based characterization of best-corrected visual acuity (BCVA) time profiles of patients with neovascular age-related macular degeneration under ranibizumab or sham treatment based on 24-month observations of BCVA in 2419 patients from randomized multicenter phase 3 trials of ranibizumab: ANCHOR, MARINA, PIER, and HARBOR. Goodness-of-fit plots and precision of parameter estimates were used for measure of accuracy.

Results

The model incorporates a long-term effect on disease progression and an additive and more potent short-term effect of ranibizumab. Response to ranibizumab treatment and progression of the disease were found to be a function of seven baseline cha

SUBMITTER: Diack C 

PROVIDER: S-EPMC8114000 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature